Vimian Group AB (VIMIAN) AI Stock Analysis

• Market Cap: €16.70B
• Dividend Yield: N/A
• Average Volume (3M): 772.80K
• Price to Earnings (P/E): 47.3
• Beta (1Y): 0.71
• Revenue Growth: 17.13%
• EPS Growth: N/A
• Country: SE
• Employees: 1,200
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.22
• Shares Outstanding: 525,964,540
• 10 Day Avg. Volume: 366,844
• 30 Day Avg. Volume: 772,803
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €37.32
• Price Target Upside: 24.17% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

• Rating: 66 Neutral
• Price Target: kr33.00 ▲(9.78% Upside)

Vimian Group AB's overall stock score is primarily driven by its strong financial performance, characterized by consistent revenue growth and robust cash flow generation. However, the high P/E ratio suggests overvaluation, which, along with neutral technical indicators, tempers the overall score. The absence of earnings call insights and corporate events means these factors did not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates a strong market position and demand for Vimian's products, supporting long-term business expansion.

Cash Flow Management

Strong cash flow management ensures financial flexibility and the ability to reinvest in growth opportunities, enhancing long-term sustainability.

Business Model Diversification

Diversified revenue streams reduce dependency on a single market segment, providing resilience against industry-specific downturns.

Negative Factors

Low Return on Equity

Low return on equity indicates inefficiency in generating profits from shareholders' investments, potentially affecting investor confidence.

Net Profit Margin

Low net profit margins may limit the company's ability to generate sufficient profits, impacting long-term financial health and growth potential.

Debt Levels

While moderate, debt levels require careful management to avoid potential financial strain, especially in volatile market conditions.

Vimian Group AB Business Overview & Revenue Model

Company Description

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. The company was incorporated in 2020 and is headquartered in Stockholm, Sweden.

How the Company Makes Money

Vimian generates revenue through multiple streams, primarily by selling veterinary diagnostic products, pharmaceuticals, and digital solutions to veterinary clinics and animal health professionals. The company leverages its expertise in the veterinary sector to develop proprietary technologies and solutions that meet the evolving needs of the market. Additionally, Vimian benefits from strategic partnerships with other organizations in the animal health industry, enabling them to expand their product offerings and reach a broader customer base. The combination of direct sales, partnerships, and a focus on innovation contributes significantly to Vimian's earnings.

Vimian Group AB Financial Statement Overview

Summary

Vimian Group AB exhibits solid financial performance with consistent revenue growth and strong cash flow generation. Profitability margins are stable, but there is room for improvement in net profit margins. The balance sheet reflects a prudent leverage strategy, though returns on equity could be enhanced.

Income Statement

Vimian Group AB shows a consistent revenue growth trajectory, with a TTM revenue growth rate of 3.4%. Gross profit margins remain strong at approximately 68.7%, indicating efficient cost management. However, net profit margins are relatively low at 5.6%, suggesting room for improvement in profitability. EBIT and EBITDA margins are stable, reflecting operational efficiency.

Balance Sheet

The company's debt-to-equity ratio is moderate at 0.43, indicating a balanced approach to leveraging. Return on equity is low at 3.3%, suggesting limited returns for shareholders. The equity ratio stands at 60.1%, showing a solid equity base relative to total assets, which enhances financial stability.

Cash Flow

Vimian Group AB demonstrates strong cash flow management with a significant free cash flow growth rate of 29.3% in the TTM period. The operating cash flow to net income ratio is healthy at 0.85, indicating efficient cash generation relative to net income. The free cash flow to net income ratio is robust at 0.84, reflecting strong cash conversion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	404.35M	374.80M	331.73M	281.31M	173.35M	137.75M
Gross Profit	277.82M	258.30M	229.43M	193.99M	122.85M	95.52M
EBITDA	87.72M	82.80M	69.19M	66.32M	40.98M	65.16M
Net Income	22.67M	18.50M	9.84M	-7.20M	6.59M	52.79M
Balance Sheet
Total Assets	1.14B	1.11B	973.68M	923.56M	640.72M	456.29M
Cash, Cash Equivalents and Short-Term Investments	67.50M	64.80M	37.50M	42.19M	55.11M	29.66M
Total Debt	294.00M	233.60M	313.80M	220.96M	180.37M	85.91M
Total Liabilities	444.80M	403.30M	446.97M	442.06M	282.08M	182.05M
Stockholders Equity	682.90M	699.90M	526.37M	481.81M	357.41M	224.02M
Cash Flow
Free Cash Flow	67.15M	43.90M	-43.48M	15.01M	4.52M	-793.00K
Operating Cash Flow	80.38M	58.10M	-28.58M	25.31M	16.01M	4.80M
Investing Cash Flow	-148.90M	-76.00M	-77.68M	-188.53M	-115.00M	-105.24M
Financing Cash Flow	97.10M	44.80M	100.55M	150.23M	123.94M	118.57M

Vimian Group AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 30.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VIMIAN, the sentiment is Negative. The current price of 30.06 is above the 20-day moving average (MA) of 29.77, below the 50-day MA of 30.14, and below the 200-day MA of 36.91, indicating a neutral trend. The MACD of 0.26 indicates Negative momentum. The RSI at 49.15 is Neutral, neither overbought nor oversold. The STOCH value of 35.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:VIMIAN.

Vimian Group AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NOLA.B	―	kr16.92B	21.44	14.17%	2.39%	0.40%	38.42%
MCAP	―	€8.35B	41.68	15.16%	―	11.30%	-14.49%
VITR	―	kr20.15B	45.23	3.34%	0.75%	-1.29%	―
VIMIAN	―	€16.70B	47.26	4.63%	―	17.13%	―
ALIF.B	―	$22.32B	65.92	7.24%	0.37%	5.14%	236.75%
EKTA.B	―	kr18.47B	67.41	2.76%	4.96%	-1.54%	-75.84%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Vimian Group AB Corporate Events

Vimian Group Initiates Share Issuance for LTIP 2025

Vimian Group AB has announced the issuance and repurchase of various classes of shares as part of its long-term incentive program (LTIP 2025). This strategic move, authorized during an Extraordinary General Meeting, aims to enhance employee engagement and align interests with shareholders, potentially strengthening Vimian’s market position and operational focus.

The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group Reports Strong Q3 2025 Performance Amid Leadership Change

Vimian Group AB reported strong financial performance for the third quarter of 2025, with a 19% increase in net revenue to EUR 104.3 million and a 9% organic growth. The company also saw a significant rise in operating profit and EBITA, indicating robust operational efficiency. Notably, the company resolved a legal dispute favorably, securing USD 40.2 million, and announced a leadership change with the appointment of an interim CEO.

The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK37.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group Announces Q3 2025 Interim Report Release

Vimian Group AB announced the release of its Interim Report for the third quarter of 2025, scheduled for October 22. The report will be presented via an audiocast by CFO and interim CEO Carl-Johan Zetterberg Boudrie and Magnus Kjellberg, CEO of the Specialty Pharma segment. This event is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction.

The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK37.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group Appoints Nomination Committee for 2026 AGM

Vimian Group AB has announced the appointment of its Nomination Committee for the 2026 Annual General Meeting, based on the ownership structure as of August 31, 2025. This development is crucial for stakeholders as it sets the stage for the upcoming AGM scheduled for April 29, 2026, where shareholders can influence the company’s strategic direction by submitting proposals to the committee.

The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK37.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Awarded USD 40.2 Million in Indemnification Dispute

Vimian Group AB has been awarded USD 40.2 million by the Superior Court of Delaware in an indemnification dispute related to its subsidiary, Veterinary Orthopedic Implants, LLC (VOI). This decision follows a USD 70 million settlement Vimian paid to DePuy Synthes in a patent dispute in April 2023. The court’s decision, combined with previous settlements with other sellers, ensures Vimian recoups more than the initial settlement amount, positively impacting its financial standing and providing a resolution to the acquisition-related indemnification process.

The most recent analyst rating on (SE:VIMIAN) stock is a Hold with a SEK37.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.

Vimian Group AB Increases Shares and Voting Power

Vimian Group AB announced an increase in the number of shares and votes due to the exercise of warrants and conversion of class C shares into ordinary shares. This change reflects the company’s strategic financial adjustments and may impact its market positioning by enhancing shareholder value and voting power distribution.

The most recent analyst rating on (SE:VIMIAN) stock is a Buy with a SEK55.00 price target. To see the full list of analyst forecasts on Vimian Group AB stock, see the SE:VIMIAN Stock Forecast page.